



# **Implementation of an Antimicrobial Stewardship Program at the Hospital and ICU Level of a Clinic in Sincelejo-Sucre**

Erick Diaz-Morales<sup>1</sup>, Ana Paola Pacheco-Hermosilla<sup>2</sup>, Daniel Esteban Castro-Mangonez<sup>2</sup> and Nerlis Pajaro-Castro<sup>1,2,\*</sup>

- <sup>1</sup> Salud Social Clinic, Sincelejo 700001, Sucre, Colombia; erick76dm@yahoo.es
- <sup>2</sup> Medical and Pharmaceutical Sciences Group, Puerta Blanca Campus, Faculty of Health Sciences and Medicine, University of Sucre, Sincelejo 700001, Sucre, Colombia; anapacheco270999@gmail.com (A.P.P.-H.); danicastromangoniz@gmail.com (D.E.C.-M.)
- \* Correspondence: nerlis.pajaro@unisucre.edu.co; Tel.: +57-3205677162

Abstract: Objectives: In this retrospective observational study, the aim is to establish how the implementation of the use of antimicrobial stewardship programs at the hospital and intensive care unit level in a Sucre Clinic in Sincelejo has had a significant impact on the improvement of the rational use of antibiotics, due to the alarming situation of increasing antibiotic resistance. Materials and methods: The methodology used was to analyze the Excel database of the Clinic in such a way as to compare the data from 2017, the period prior to the implementation of the antimicrobial stewardship program (ASP), with the subsequent evolution between the years 2018 and 2022, in relation to the institutional records of four antibiotics-ceftriaxone3, ciprofloxacin4, meropenem5, and vancomycin6, measured in defined daily dose (DDD). Results: According to the defined daily dose values obtained for the four antibiotics, a reduction in the defined daily dose was identified in the post-implementation period. On the other hand, considering the DDD reported by the World Health Organization for each of the antibiotics, significant differences were verified in comparison with those obtained in the clinic in the hospitalization and intensive care unit services. Conclusions: In conclusion, in the clinic, a reduction in the defined daily dose was verified in the period after the implementation of the antimicrobial stewardship program compared to the previous period, both in the hospitalization and intensive care unit, as well as having a mild-to-large effect with Cohen's D.

Keywords: antibiotics; ASP; ceftriaxone; ciprofloxacin; meropenem; vancomycin

# 1. Introduction

The rise of antibiotic resistance is a global health threat associated with increased mortality and higher healthcare costs. In fact, the United Nations General Assembly met to address this threat in September 2016, indicating a current issue that requires immediate solutions. In addition to resistance, antibiotics are a common cause of serious adverse effects that compromise patient health. Therefore, the primary method to decrease antibiotic resistance and adverse effects is to minimize unnecessary antibiotic use. To mitigate suboptimal antibiotic use and improve patient outcomes, the World Health Organization, Centers for Disease Control and Prevention (CDC), Joint Commission, Centers for Medicare, and Medicaid Services (CMS) have advocated for antibiotic stewardship programs (ASPs) [1].

Antibiotic use and prescription in approximately 50% of cases is inappropriate, thus promoting the emergence of bacterial resistance, as mentioned above. Therefore, ASPs are necessary, and aim to facilitate the rational use of antibiotics and improve the outcomes of patients receiving antibacterial treatment [2].

Antimicrobial resistance can be prevented by interventions aimed at reducing the overprescription of antibiotics to hospitalized patients through ASPs, characterized by being based on the following seven basic elements: leadership commitment, multidisciplinary



Citation: Diaz-Morales, E.; Pacheco-Hermosilla, A.P.; Castro-Mangonez, D.E.; Pajaro-Castro, N. Implementation of an Antimicrobial Stewardship Program at the Hospital and ICU Level of a Clinic in Sincelejo-Sucre. *Sci. Pharm.* 2024, *92*, 39. https://doi.org/ 10.3390/scipharm92030039

Academic Editor: William A. Donaldson

Received: 14 May 2024 Revised: 17 June 2024 Accepted: 18 June 2024 Published: 17 July 2024



**Copyright:** © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). team, situation assessment, interventions to improve antibiotic use, surveillance, reporting, and education. These are designed to optimize antibiotic therapy, leading to significant reductions in antibiotic administration and consumption, bringing the benefit of decreases in antibiotic resistance, toxicity, and costs. Guidelines for empiric therapy, checklists, dedicated teams, mandatory rules, alerts on antibiotic misuse, and the monitoring of antibiotic consumption have been described as ASP interventions that had significant benefits in clinical outcomes [3].

In the case of Colombia, there have been many ASP implementations, in which beneficial results have been achieved in terms of rational antibiotic use and reducing the negative impact of inappropriate antibiotic consumption. Among these is the Colsubsidio Children's Clinic for June 2016 to December 2019, in which the identification of controlled antibiotics, the review of medical records by the infectologist, the characterization of antibiotic prescriptions, the analysis and identification of ASP indicators, the audit and feedback, and finally the education and reports were proposed [4].

Another implementation of an ASP was in the Pediatric Hospital of IV level in Bogotá (HOMI), with which they achieved beneficial results, such as the optimization of antibiotic use, the improvement of clinical outcomes, a reduction of 20 to 50% of antimicrobial use, and a significant cost reduction [5].

This article aims to establish how the implementation of the use of antimicrobial stewardship programs at the hospital and ICU level in a clinic in Sincelejo Sucre has had a significant impact on the improvement of the rational use of antibiotics.

### 2. Materials and Methods

A retrospective observational study of an Excel database of the Salud Total clinic at the hospitalization level and in the ICU from 2018 to 2022 was performed. This is a mediumlevel clinic. Regarding its facilities, they have 29 beds for ICU, 125 in hospitalization, and 6 operating rooms. Twenty beds are enabled, which are distributed as follows: 10 intensive, 4 intermediate, and 6 basic neonatal beds. The implementation of ASPs in this hospital was carried out in 2018. The program is formed of an infectologist, a microbiologist– pharmacologist physician, a nurse, and a chemist. The mechanism of operation of this program is through a persuasive methodology, which consists of the use of guidelines and therapeutic recommendations for the use of antibiotics against certain infectious pathologies; likewise, as a fundamental component, it involves the initial individual or initial group education of clinicians, followed by continuing education. In this study, the antibiotics selected for analysis of the ASP were ceftriaxone, ciprofloxacin, meropenem, and vancomycin. The objective was to analyze the pre-ASP (2017) and post-ASP (2018-2022) periods in relation to the use of the four antibiotics mentioned, measured in defined daily doses (DDD) per 100 beds/day, allowing us to establish the impact of the use of the program. Analysis of DDD before the implementation of the 2017 pre-ASP program was also performed, comparing whether antibiotic use was reduced.

Statistical analysis: Data were collected in a database in the Excel program and the results are expressed as the average monthly DDD for each year of pre-ASP and post-ASP. To evaluate the effect of the ASP program, Cohen's D was used, whereby values lower than 0.20 indicate no effect, and values between 0.21 and 0.49 refer to a small effect; likewise, values oscillating between 0.50 and 0.70 indicate a moderate effect. Finally, values higher than 0.80 indicate a large effect [6,7]. The statistical analysis was performed using the statistical program Prism 5 for Windows, version 5.0. To determine the existence of significant difference between pre-ASP and post-ASP DDD data, an analysis of variance with one-way ANOVA was performed; previously, the normality of the data was evaluated with the Shapiro–Wilk test. In all cases, the *p* value was greater than 0.05. Finally Dunnet's post-test was run. *p* values less than 0.05 indicate a significant difference between the pre-ASP and post-ASP periods.

## 3. Results

The antibiotic optimization program was implemented from the year 2018, corresponding to the post-ASP period; the year 2017 is the pre-ASP period. Therefore, below are the results of defined daily doses for the antibiotics ceftriaxone, ciprofloxacin, meropenem, and vancomycin for hospitalization and ICU (intensive care unit) services in a clinic in Sincelejo, Sucre (Figures 1–4), where the decrease in DDD (stands for defined daily dose) from the post-ASP period can be evidenced.



**Figure 1.** Ceftriaxone DDD in hospitalization and ICU settings. The gray line vertical represents the division of the pre-proa and post-proa period in the implementation of the program in the clinic.



**Figure 2.** Ciprofloxacin DDD in hospitalization and ICU settings. The gray line vertical represents the division of the pre-proa and post-proa period in the implementation of the program in the clinic.



**Figure 3.** Meropenem DDD in hospitalization and ICU settings. The gray line vertical represents the division of the pre-proa and post-proa period in the implementation of the program in the clinic.



**Figure 4.** Vancomycin DDD in hospitalization and ICU settings. The gray line vertical represents the division of the pre-proa and post-proa period in the implementation of the program in the clinic.

In order to determine the effect of the antibiotic optimization program, Cohen's D analysis was performed, and the results are shown in Table 1.

Table 1. Cohen's D for hospitalization and ICU settings compared to year 2017 (pre	-ASP).

Antibiotics		Ho	spitalizati	ion	ICU					
	2018	2019	2020	2021	2022	2018	2019	2020	2021	2022
Cextriaxone	0.38	1.18	1.22	1.91	1.2	0.63	0.2	0.52	0.2	0.73
Ciprofloxacin	1.13	1.03	1.17	1.29	1.23	0.57	0.36	0.43	0.03	0.93
Meropenem	0.58	0.91	0.85	1.74	0.6	1.68	0.78	0.72	0.35	0.96
Vancomycin	1.25	0.33	1.66	0.04	0.35	1.05	0.57	0.76	0.99	0.01

Analyzing the results obtained from Table 1, it is evident that for the case of the antibiotic ceftriaxone, in the first year of implementation of the antibiotic optimization program, the effect was small in hospitalization, but in subsequent years, a large effect is observed, and in ICU for the years 2018, 2020, and 2022, there is a moderate effect, but in the years 2019 and 2021, there is no effect.

For the case of ciprofloxacin, a large effect is evident from the first year of implementation of the ASP until the last year of the study, and in the ICU, it had a moderate effect in the first year, but in the second and third years, the effect was small, while for the year 2021, the program had no effect; perhaps this result is due to the COVID-19 pandemic, because for the last year, the effect was large.

The results for the antibiotic meropenem show a moderate effect in the first year, but over the years, the effect becomes large in hospitalization, and in the ICU, a large effect is observed in the first and last years; a moderate effect in the second and third years; and for 2021, a small effect.

The results for the antibiotic vancomycin show a large effect in the first and third years, and a small effect in 2019 and 2022, while for 2021, there was no effect in hospitalization, and for ICU, the first and fourth years show a large effect; the second and third years show a moderate effect; and for 2022, there was no effect. In the case of hospitalization, the impact of the ASP was greater than in the ICU, in addition, for 2021, in the ICU, in the case of all antibiotics, no effect of the ASP was found, perhaps as a response to the COVID-19 pandemic.

On the other hand, considering the DDD reported by the WHO for each of the antibiotics, we evaluated the significant differences compared with the DDD obtained in the clinic in the hospitalization and ICU services, as shown in Table 2. A Shapiro–Wilk test was performed to determine the normality of the data, and in all cases, the *p* value was greater than 0.05; therefore, all data are normal. After checking the normality of the data, we proceeded to perform a one-way ANOVA to compare the DDD of the year 2017 (pre-ASP) with the years from 2018 to 2022 (post-ASP), for which Dunnet's post-test was performed. The ANOVA analysis for the hospitalization data gives us as a result with a *p*-value less than 0.05, proving that there is a statistically significant difference; with the post-test, it was proven that there is a significant difference between the pre-ASP and post-ASP. Therefore, it is demonstrated that the antibiotic optimization program is effective. But, for the case of meropenem and ceftriaxone in hospitalization, no significant difference was observed between 2017 and 2018.

**Table 2.** Comparison of the daily doses defined by the World Health Organization (WHO) and the antimicrobial stewardship program.

Antibiotics	WHO	Hospitalization						ICU					
		2017	2018	2019	2020	2021	2022	2017	2018	2019	2020	2021	2022
Cextriaxone	2	13.52	16.44	6.67	5.05	4.60	5.26	1.73	3.21	2.02	4.84	2.13	2.20
Ciprofloxacin	1	5.92	10.73	2.65	1.96	1.62	1.58	4.40	2.55	2.02	2.44	4.74	2.00
Meropenem	3	11.97	15.63	6.03	6.35	7.10	8.08	40.85	42.00	22.53	23.93	32.53	18.61
Vancomycin	2	4.73	8.52	3.86	4.40	4.62	5.58	9.96	18.99	2.02	15.06	17.48	9.99

Analysis of the ICU outcomes for ceftriaxone and vancomycin tells us that there is no significant difference between pre-ASP and post-ASP (*p* value greater than 0.05), while for the case of ciprofloxacin and meropenem, there are significant differences between pre-ASP and post-ASP DDD (*p* value less than 0.05).

Now, if we compare the DDD given by the WHO with that obtained each year, it is evident that for the case of meropenem hospitalization in 2019, there were no significant differences; for ciprofloxacin from 2019 to 2022, there were no significant differences; and for ceftriaxone from 2020 to 2021, there were also no significant differences. For the rest, there were significant differences. What is striking is that the years corresponding to the post-ASP are those that did not give differences compared to the WHO DDD, which shows that the DDD values are very close to those recommended by the WHO, and this in turn demonstrates the effectiveness of the ASP in this clinic.

For the case of the ICU, there is no evidence of significant differences between the DDD values recommended by the WHO, and for ceftriaxone from 2017 to 2022 and ciprofloxacin from 2018 to 2022, there were no significant differences. This demonstrates the relevance of ASPs because we have comparable DDD data with those provided by the WHO.

#### 4. Discussion

The implementation of the ASP at the Salud Total Clinic has proven crucial in improving the appropriate use of antibiotics and reducing the risk of antimicrobial resistance. The results indicate that the ASP has achieved a significant reduction in inappropriate antibiotic use, particularly in hospitalization, where large and sustained effects were observed over time. Furthermore, the alignment of the DDD with the WHO's recommendations underscores the effectiveness of the ASP in standardizing and optimizing administered doses. Although the impact in the ICU was variable and diminished during the COVID-19 pandemic, the data still show improvements in antibiotic administration. These findings highlight the importance of maintaining and adapting the ASP to ensure proper antibiotic management, thereby enhancing patient care quality and combatting antimicrobial resistance [8].

It is important to mention that the effect of the antimicrobial optimization program at the Salud Total clinic was reflected in the good use of the four antibiotics analyzed. Since the DDD used over the years were correct and were used only in the case in which they were needed, this has had an impact not only on reducing the clinic's bacterial resistance, but also on better health outcomes for its patients.

To improve the program, analysis of all the antibiotics used in the clinic should continue to be carried out and also the entire team should be trained so that the use of each antibiotic used can be improved, depending on the clinical case that the doctor is facing.

Another similar study on the implementation of an ASP in an intensive care unit against multidrug-resistant Gram-negative bacteria infections has shown that the program is an effective and safe tool that reduces and adjusts the use of antimicrobials in clinical practice. This has a double benefit—on the one hand, it reduces antibiotic pressure and, therefore, the selection of multidrug-resistant strains, and on the other hand, it reduces the possible deleterious effects on the individual patient and even improves the prognosis by adjusting the choice of drug, the dosage, and the possible adverse effects and interactions; as in our research, everything was reflected in the use of optimization indicators such as DDD(defined daily dose) [9]. In the implementation of this same program in the intensive care unit of a Public Hospital of Santa Elena in Ecuador, the amount of antibiotics consumed between 2018 and 2019 was evaluated, in which the use of cephalosporins such as ceftriaxone, cefepime, and ceftazidime was reduced and the consumption of ampicillin + sulbactam and Piperacillin + tazobactam was increased. Comparing it with our study, it can be seen how the implementation of the ASP allows for the correct optimization of antibiotic use against the different infections of patients [10].

Antimicrobial stewardship programs have had a great impact at international, national, and local levels, allowing for the improvement and reduction of the negative ecological impacts of their use. Spain is one of the countries with the highest consumption of antimicrobials globally. It is estimated that up to 45% of patients admitted to Spanish hospitals receive at least one dose of antibiotics during their stay. At the University Clinical Hospital of Spain, in the Urology Department, the result was a reduction in the average DDD/100 stays of meropenem, ciprofloxacin, and ceftriaxone. This made it possible to optimize communication and identification of points for the improvement of its clinical practice and daily control of the use of antimicrobials, which made it possible to reduce the use of certain molecules, especially in scheduled surgical procedures [11]. It is important to mention that due to the current resistance of antibiotics, it is necessary to use ASPs to improve their use, allowing safe interventions and processes. In the case of three Portuguese hospitals, a participatory approach was used between researchers and workers, resulting in a clinical decision support system and real-time surveillance that integrates patient, microbiology, and pharmacy data and facilitates clinical decision making, this means that resistance is monitored, and antibiotic prescription is tailored to the patient's needs. This is the case of the way in which the program was implemented at the Salud Social Clinic, in which the ASP work team complements the physician in the selection of antibiotics by means of persuasive methodology [12]. The above is complemented by the information found in an article on the effectiveness of an ASP in a tertiary hospital in Vietnam, in March 2016; the Ministry of Health of this country issued 772 guidelines for antibiotic prescription in hospital settings, with which, as they were updated, it was possible to reduce the consumption of antibiotics and improve clinical outcomes among patients with infection [13,14].

In another study, the implementation of the use of antimicrobials is presented as the main tool for optimizing hospitals, improving clinical outcomes, and reducing adverse effects and the spread of resistance. The result obtained with respect to the consumption of all the antibacterials studied by the ASP decreased both the per stay and per discharge values from 36.62 to 35.72 DDD/100 stays (-2.5%) and from 236.02 to 227.03 DDD/100 discharges, respectively (-3.8%). Among the antimicrobials that decreased the most was ciprofloxacin by 20.40% [15]. At the Carlos Van Buren Hospital in Valparaiso, Chile, the implementation of an ASP in the adult emergency unit was used for the treatment of high urinary tract infection, in which the impact on the consumption of amikacin and ceftriaxone was determined; the results were measured in DDD, where a decrease in the consumption

of ceftriaxone and an increase in amikacin were observed [14]. At the Hospital de Mexico in 2014, an ASP program was implemented in the orthopedics service as a protocol for pre-surgical prophylaxis, which resulted in a decrease in the use of beta-lactams, mainly cephalosporins and penicillins, indicating an improvement in the optimization of antibiotic use. Those that increased are vancomycin, trimethoprim-sulfamethoxazole, clindamycin, and gentamicin. With respect to the results, it can be said that it is evident that the intervention by ASP has produced important changes in consumption patterns, which on the one hand shows compliance with the intervention, which may indicate that there is an improvement in the quality of prescription of antibiotics used for antibiotic prophylaxis [15].

In the case of Colombia, several ASP implementations have also been carried out in order to reduce the irrational use of antibiotics and control their use for the benefit of the patient. In the Colsubsidio Children's Clinic for the years June 2016 to December 2019, this involved the identification of controlled antibiotics, a review of medical records by the infectologist, the characterization of antibiotic prescriptions, the analysis and identification of ASP indicators, an audit, and feedback, as well as education and reports. In the same way, this program has been implemented in the department of Sucre in the Salud Total Clinic, since there are few clinics in this territory that have obtained good results thanks to these improvements [4]. Another ASP implementation was in the IV level Pediatric Hospital in Bogotá (HOMI), with which they achieved beneficial results, such as the optimization of antibiotic use, an improvement of clinical outcomes, a reduction of 20 to 50% in the use of antimicrobials, and a significant cost reduction [5].

## 5. Conclusions

According to the results obtained, we can conclude that the antibiotic optimization program is an effective tool to reduce antibiotic consumption and promote the appropriate use of antibiotics, because our results showed a reduction in DDD in the post-ASP period compared to the pre-ASP period, both in hospitalization and in the ICU.

Author Contributions: Conceptualization, E.D.-M., A.P.P.-H., D.E.C.-M. and N.P.-C.; methodology, E.D.-M., A.P.P.-H., D.E.C.-M. and N.P.-C.; formal analysis, E.D.-M., A.P.P.-H., D.E.C.-M. and N.P.-C.; investigation, E.D.-M., A.P.P.-H., D.E.C.-M. and N.P.-C.; resources, E.D.-M., A.P.P.-H., D.E.C.-M. and N.P.-C.; data curation, E.D.-M., A.P.P.-H., D.E.C.-M. and N.P.-C.; writing—original draft preparation, E.D.-M., A.P.P.-H., D.E.C.-M. and N.P.-C.; writing—original draft preparation, E.D.-M., A.P.P.-H., D.E.C.-M. and N.P.-C.; writing—original draft preparation, E.D.-M., A.P.P.-H., D.E.C.-M. and N.P.-C.; visualization, E.D.-M., A.P.P.-H., D.E.C.-M. and N.P.-C.; supervision, E.D.-M., A.P.P.-H., D.E.C.-M. and Second Seco

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

**Data Availability Statement:** Non-digital data supporting this study are curated at the Salud Social clinic in Sincelejo-Sucre-Colombia.

**Acknowledgments:** The authors would like to thank the Salud Social clinic in Sincelejo-Sucre-Colombia for providing the information for the study and the University of Sucre. Minciencias call for postdoctoral stays oriented by missions 934, contract 320-2023.

**Conflicts of Interest:** Authors declare that there are no conflicts of interest regarding the publication of this article.

#### References

- 1. Gross, A.E.; Hanna, D.; Rowan, S.A.; Bleasdale, S.C.; Suda, K. Successful Implementation of an Antibiotic Stewardship Program in an Academic Dental Practice. *Open Forum Infect. Dis.* **2019**, *6*, ofz067. [CrossRef] [PubMed]
- Simões, A.S.; Maia, M.R.; Gregório, J.; Couto, I.; Asfeldt, A.M.; Simonsen, G.S.; Póvoa, P.; Viveiros, M.; Lapão, L.V. Participatory implementation of an antibiotic stewardship program supported by an innovative surveillance and clinical decision-support system. J. Hosp. Infect. 2018, 100, 257–264. [CrossRef] [PubMed]

- Riaño-Galvis, O.; Cerinza-Villanueva, D. Caracterización de un Programa de Optimización de Antimicrobianos en la Prescripción de Ampicilina/Sulbactam en un Hospital Pediátrico. 2021. Available online: https://repository.urosario.edu.co/bitstream/ handle/10336/30924/Caracterizaci%F3n%20de%20un%20PROA%20.pdf;jsessionid=DE8605C55B057267ED824AD9D0241EF9 ?sequence=1 (accessed on 15 March 2023).
- Tobar, F. Experiencia PROA Clínica Infantil Colsubsidio Implementación a su Impacto. 2019. Available online: http: //www.saludcapital.gov.co/DSP/Infecciones%20Asociadas%20a%20Atencin%20en%20Salud/Comites/2019/Diciembre/ PROA\_2019.pdf (accessed on 10 March 2023).
- 5. Moreno, G. Programa de Optimización del Uso de Antibioticos (PROA), Experiencia en un Hospital Pediátrico de IV Nivel en Bogota (Colombia). 2019. Available online: https://webbertraining.com/files/library/docs/828.pdf (accessed on 10 March 2023).
- 6. Caycho, T.; Ventura-León, J.; Castillo-Blanco, R. Magnitud del efecto para la diferencia de dos grupos en ciencias de la salud. *An. Sist. Sanit. Navar.* **2016**, *39*, 459–461. [PubMed]
- 7. Cohen, J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed.; Erlbaum: Hillsdale, MI, USA, 1998.
- Martínez-de la Cruz, P.; Moreno-Núñez, L.; Álvarez-Atienza, S.; Sanz-Márquez, S.; Valverde-Canovas, J.F.; Losa-García, J.E. Discontinuation of antibiotics through an antimicrobial treatment optimization program in patients attended in Emergency Departments with low suspicion of infection. *Enferm. Infecc. Microbiol. Clin.* 2022, 41, 7. [CrossRef]
- 9. Ruiz-Ramos, J.; Ramírez-Galleymore, P. Antibiotic optimization programs in the intensive care unit for infections caused by multidrug-resistant gram-negative bacilli. *Med. Intensiv.* 2023, 47, 99–107. [CrossRef]
- 10. Ruales-Carrion, P.; Mariscal-Santi, W.; Jimenez-Jimenez, W. La implementación de un programa de optimización de antibióticos en la unidad de cuidados intensivos de un Hospital Público de Santa Elena. *Revista* **2021**, *133*, 9–16. [CrossRef]
- 11. Martinez, G. Intervención en el Servicio de Urología Mediante un Programa de Optimización del uso de Antimicrobianos. 2022. Available online: https://digitum.um.es/digitum/handle/10201/125412 (accessed on 2 April 2023).
- Nguyen, H.Q.; Nguyen-Thi, H.-Y.; Huynh, P.-T.; Le, N.D.T.; Nguyen, N.T.-Q.; Hsia, Y. Effectiveness of an enhanced antibiotic stewardship program among pediatric patients in a tertiary hospital in Vietnam. *J. Hosp. Infect.* 2022, 127, 121–128. [CrossRef] [PubMed]
- Collado, R.; Losa, J.; Alba, E.; Toro, A.; Moreno, L.; Pérez, M. Evaluación del consumo de antimicrobianos mediante DDD/100 estancias versus DDD/100 altas en la implantación de un Programa de Optimización del Uso de Antimicrobianos. *Rev. Esp. Quimioter.* 2015, 28, 317–321. [PubMed]
- 14. Cruz, R.; Sandoval, R.; González, G.; Pérez, P.; Sánchez, L. Impact on the consumption of amikacin and ceftriaxone in an adult emergency unit, after the implementation of a guide for the treatment of high urinary tract infections. *Infection* **2019**, *23*, 313. [CrossRef]
- Rodríguez-Baño, J.; Paño-Pardo, J.R.; Alvarez-Rocha, L.; Asensio, Á.; Calbo, E.; Cercenado, E.; Cisneros, J.M.; Cobo, J.; Delgado, O.; Garnacho-Montero, J.; et al. Antimicrobial use optimization programs (PROA) in Spanish hospitals: GEIH-SEIMC, SEFH and SEMPSPH consensus document. *Dis. Infect. Microbiol. Clin.* 2012, 30, e1–e22. [CrossRef]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.